Novo Nordisk A/S is seeking approval from Chinese regulators to launch its weight-loss pill Wegovy.

Novo Nordisk A/S CEO Mike Doustdar stated that the company plans to soon seek approval from Chinese regulators for its weight-loss pill Wegovy, aiming to catch up with Eli Lilly and Co (LLY.US) in the Chinese market. Doustdar said the company will submit data on oral Wegovy to regulators within a few months to seek approval, and expects competition from generic manufacturers to emerge starting in the second quarter of next year. Although Novo Nordisk has regulatory data protection until early next year, the patent for semaglutide—the active ingredient in its blockbuster drugs Wegovy and Ozempic—in China

AASTOCKSJun 16 15:20

Innovent Bio granted 5,000 stock options and 105,200 restricted shares.

Innovent Bio (01801) announced that, on June 15, 2026, the company granted 5,000 share options to one grantee and 105,200 restricted shares to 22 grantees under the terms of its 2024 Share Plan, subject to acceptance by the grantees. All grantees are non-associated employees of the Group (not part of senior management).

Sina HK StocksJun 16 08:59

Express News | Innovative drug stocks rebounded with volatility, with RemeGen surging over 10%.

BreakingsJun 12 13:39

China Galaxy Securities: Innovative Drugs Remain in High Demand as Emerging Pillar Sector Undergoes Strategic Upgrade

New regulations on pharmaceutical sales representatives, introduced alongside anti-corruption measures in the healthcare sector, have taken effect. The threshold for criminal liability for commercial bribery has been lowered, and industry-wide compliance reforms are reshaping the pharmaceutical ecosystem, which is expected to significantly alter the landscape of clinically used drugs.

Zhitong FinanceJun 12 11:43

As the GLP-1 Race Heats Up, How Can Investors Position Themselves for the Next Wave of Innovation?

Seeking AlphaJun 11 03:19

Innovent Biologics (IVBXF) Receives a Buy From UBS

TipRanksJun 10 08:26 · Ratings